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PEMENCILAN RNA APTAMER YANG KHUSUS MENGIKAT TERHADAP 
PROTIN ANTIGEN 16 kDa Mycobacterium tuberculosis 
ABSTRAK 
Tuberkulosis (TB) adalah sejenis penyakit berjangkit tertua yang disebabkan 
oleh Mycobacterium tuberculosis (M.tb) yang memberi kesan ke atas manusia. 
Terdapat beberapa diagnosis makmal yang tersedia untuk pemeriksaan TB seperti 
kaedah pengkulturan media, mikroskopi calitan kahak dan pengamplifikasian asid 
nukleik  untuk mendiagnosis pesakit TB aktif. Walau bagaimanapun, kaedah-kaedah 
tersebut tidak dapat mengesan jangkitan TB laten (LTBI). Walaupun Esei 
Pengesanan Interferon Gamma Terbebas (IGRAs) telah diperkenalkan untuk 
mendiagnosis LTBI, namun demikian ujian ini merupakan ujian makmal yang mahal 
dan memerlukan proses makmal yang banyak. Ujian ini juga tidak dapat diakses oleh 
negara-negara miskin yang mempunyai bebanan kes TB yang tinggi kerana kos dan 
tidak mempunyai kemudahan membuat diagnosis secara terus. Oleh itu, teknologi 
pendiagnosan secara terus yang baharu sangat diperlukan untuk menambah baik 
diagnosis LTBI yang sedia ada agar lebih menjimatkan dan senang dilaksanakan 
terutamanya kepada negara-negara yang tidak mempunyai kemudahan fasiliti yang 
baik. Sehingga kini, aptamer telah mendapat banyak perhatian kerana ciri-cirinya 
yang dikenalpasti mampu menyerupai fungsi antibodi yang mengikat sasaran dengan 
nilai pengikatan dan spesifikasi yang tinggi. Protin 16 kDa daripada M.tb telah 
dipilih sebagai sasaran utama kajian kerana kepentingannya dalam TB laten dan 
sifatnya yang imunodominan. Oleh itu, kajian ini dijalankan bagi memencil dan 
mencirikan aptamer RNA yang spesifik ke atas protin 16 kDa. Dengan menggunakan 
kaedah Pengkayaan Ligan Secara Eksponensial Melalui Evolusi Sistematik 
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(SELEX), RNA aptamer yang spesifik ke atas protin 16 kDa telah berjaya 
dipencilkan dan dicirikan. Aptamer yang dipencilkan telah diklusterkan mengikut 
jujukan homologi nukleotidanya, manakala struktur sekunder, motif dan analisa G-
quadruplex telah dijalankan dengan menggunakan perisian atas talian secara 
percuma. Dalam kajian ini, esei pelekatan (EMSA) dengan menggunakan kaedah gel 
elektroforesis agarosa untuk mengenalpasti pengikatan dan nilai pemalar pemisahan 
(Kd) untuk setiap RNA aptamer yang dipencil. Daripada lima kluster aptamer RNA 
telah dipencilkan, kluster TB_APG01 didapati mempunyai jujukan nukleotida 
dengan kekerapan yang paling tinggi (14/104) dan nilai Kd 6.428±4.97 µM, namun 
demikian kluster TB_APG04 telah dikenalpasti sebagai aptamer yang paling kuat 
kerana mempunyai nilai Kd yang paling rendah (3.935±1.60 µM) walaupun hanya 
mempunyai 2/104 klon. Secara kesimpulannya, kajian ini telah berjaya memencilkan 
RNA aptamer yang mengikat kepada protin 16 kDa dan berkemungkinan boleh 












ISOLATION OF RNA APTAMERS SPECIFIC TOWARD 
16 kDa Mycobacterium tuberculosis ANTIGEN PROTEIN 
ABSTRACT  
Tuberculosis (TB) is an old, infectious disease scourge caused by 
Mycobacterium tuberculosis (M.tb) that affects human. There are several laboratories 
diagnostic methods available for TB screening such as sputum smear microscopy, 
culture and nucleic acid amplification that can diagnose patients with active TB. 
However, the methods are not for detection of latent TB infection (LTBI). Despite 
the advent of Interferon Gamma Release Assay (IGRAs) for diagnosis of LTBI, the 
test is expensive and laborious. The test is also not accessible for poor countries that 
have high TB burden due to cost and lack of rapid point-of-care setting. Thus, a new 
point-of-care technology is urgently needed to improve the current LTBI diagnosis to 
more economical and easily implemented technology especially for low resource 
settings countries. So far, aptamers have received considerable attention due to its 
properties that could imitate function of antibody against the target with high 
specificity and affinity. The 16 kDa protein of M.tb. was selected as a prime 
candidate for this study due to its importance in immunodominant property and 
tuberculosis latency. Thus, this study was aimed to isolate and characterise the RNA 
aptamers against the 16 kDa protein. By performing Systematic Evolution of Ligands 
by Exponential Enrichment (SELEX) method using nitrocellulose membrane, the 
RNA aptamers against 16 kDa protein were successfully isolated and characterised. 
The isolated aptamers were then clustered together based on their nucleotide 
homology sequences, while the secondary structure, motif sequence and G-
quadruplex analysis were identified using free online software. Electrophoretic 
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Mobility Shift Assay (EMSA) was performed using agarose gel electrophoresis to 
determine the binding and the dissociation constant (Kd) value for each isolated 
RNA aptamer. Out of five isolated clusters of RNA aptamers, the cluster 
(TB_APG01) was had the nucleotide sequences with the highest frequency clones 
(14/104) and Kd value 6.428±4.97 µM, however the cluster TB_APG04 was 
recognized as the strongest aptamer with the lowest Kd value (3.935±1.60µM) 
although only have 2/104 clones. As a conclusion, this study was successfully 
isolated the RNA aptamers that bound to the 16 kDa protein and maybe useful for 

















1.1 Research Background 
The discovery of several laboratory diagnosis of tuberculosis infection (TB) 
had one of the most critical impacts on society since earlier treatment will give hope 
to the TB patients and prolonged their lifespan. Nevertheless, the impingement of the 
disease can be distressing even today, particularly in poor regions that suffering high 
burdens of TB since most of the introduced TB diagnostics were uneconomical, not a 
point-of-care settings and need to be conducted by highly technical expertise that 
lead to undermine the effort of the global health department to combat the mortality 
rate of TB worldwide. 
Contempt of all advanced technology has been brought out for TB diagnostic, 
a new tool for TB diagnosis that is feasible and implemented easily is needed to be 
grown to improve the recurring limitations of the other methods. Hence, the idea of 
generating aptamers against specific target proteins in Mycobacterium tuberculosis 
(M.tb) for TB diagnosis is one of the first steps for producing low cost, rapid and 
precise diagnostic tools. 
This study is aimed to isolate and characterise the RNA aptamers against the 
16 kDa protein by performing Systematic Evolution of Ligands by Exponential 




1.2 The Rationale of the Study 
The burden of tuberculosis (TB) is one of the major public health concerns 
nowadays that affected humankind leading to various kinds of TB treatment, and 
diagnostic tools have been evolved in order to cope with the high mortality of TB 
patients annually. Besides, the efforts for control of TB have been severely hampered 
by the emergence of drug resistance (Nachega and Chaisson, 2003) since it raises the 
possibility for coming back to an era which drugs are no longer beneficial (Gandhi et 
al., 2010). Thus, in order to treat the suspected infected patients earlier, the fast and 
reliable technique needs to be developed to diagnose the patients with latent TB 
because failure to identify and treat latently infected individuals will allow the 
reactivation of M.tb and the chain of transmission to continue becomes active TB 
disease. 
Several laboratory diagnoses of TB infection have been widely used, 
including detection of antibody, nucleic acid amplification, microscopy, culture and 
also biochemical characteristics. The sputum smear microscopy, culture-based 
methods and rapid molecular tests (Xpert® MTB/RIF assay) are the diagnostic tests 
for TB that have been endorsed by the World Health Organisation (WHO, 2019). 
However, all this tests have limited specificity, time-consuming which takes 2-3 
weeks for detection under optimal condition, relatively expensive for poor country 
where TB is most prevalent, and the technology is still too complex to be feasible for 
TB control programs respectively (Drobniewski et al., 2003; Srivastava et al., 2013). 
Therefore, there is a need to develop strictly accurate, simple to use and new point-
of-care tool technology for diagnosing TB. 
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Aptamers are a `chemical antibodyʹ that used as detecting agents which is 
easily implemented that offers much more advantages and exciting features such as 
selected entirely in vitro process, non-immunogenic and can be easily modified 
which set them apart from the antibodies (Meyer et al., 2011). Besides, an aptamer 
also has shown high strength of binding affinity in a wide range of applications and 
the type of target molecules are unlimited which is a convincing substitute for an 
antibody (Song et al., 2012). 
The reliable biomarkers as a mark of detection were needed to ascertain the 
exact diagnosis of latent TB (LTBI). The 16 kDa antigen protein also known as heat 
shock protein (HspX) or Acr protein (α-crystalline protein homolog) have been 
highlighted to be desirable targets for a new diagnosis of LTBI and have been 
reported significance to its latency (Siddiqui et al., 2011). Thus, with the importance 
of the 16 kDa protein as a biomarker for LTBI as mentioned above, it is convincing 
to choose the antigen as a binding ligand to isolate RNA aptamers in this study. 
Last but not least, the aptamer is believed will enhancing TB diagnostic 
especially in low resource setting and developing countries as it is cheap and thermal 
stable. In addition, aptamer also has a potential to replace the use of drug and 





1.3 Objectives of the Study 
1.3.1 General Objective 
The general objective of this study is to isolate and characterise the potential 
RNA aptamers as a detection agent that can bind specifically to 16 kDa antigen 
protein of Mycobacterium tuberculosis for better LTBI diagnosis.  
1.3.2 Specific Objectives 
The specific objectives are as follow: 
1. To prepare RNA pool for RNA aptamers selection against 16 kDa antigen 
protein of Mycobacterium tuberculosis. 
2. To isolate, identify the sequences and predict the secondary structure of the 
potential RNA aptamers candidates after selection with that 16 kDa antigen 
protein of Mycobacterium tuberculosis. 
3. To evaluate the binding affinity by determining the dissociation constant (Kd) 







2.1 Epidemiology of Tuberculosis 
Human tuberculosis (TB) is a daunting public health challenge that leads 
significantly to illness and affecting millions of lives around the world (Chang et al., 
1996). TB has been reported by the World Health Organisation (WHO) as one of the 
top ten causes of mortality from a single infectious agent compare to HIV/AIDS. 
Generally, a relatively small proportion (5-10%) of the estimated individual infected 
annually with TB will progress into TB disease throughout their lifetime. However, 
the probability is much higher among HIV patient and people with malnutrition and 
diabetic problem (WHO, 2018). Globally, it has been estimated that 10.0 million 
people (range, 9.0-11.1 million) affected by the TB disease with accounted for 57 %, 
32 % of women and 11 % of children in 2018 but the highest burden is in men 
(WHO, 2019) 
The severity of national epidemics cases relative to population (incident rate) 
varies widely among country as can be seen in Figure 2.1. Most of the countries 
affected in 2018 were South-East Asia and Africa which reached the incident rates 
above 300 per 100 000 population. The lowest incident rates usually found 
predominantly in high-income countries including Western Europe, United State of 
America, New Zealand, Japan, Canada and Australia. In these countries, the 
incidence rate per 100 000 population is less than 10 incidences (WHO, 2019). In 
Malaysia, the death rate due to TB in 2018 is 6.6 per 100 000 population, which 
Selangor recorded the highest cases, 5071 cases followed by Sabah, 5008 cases as 
reported by Datuk Dr Noor Hisham Abdullah, the Health Director General in 
BERNAMA on March 26, 2019. Similar to other developing countries, TB cases in 
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Malaysia are clustered in populated density, poor housing conditions or environment 
and low socioeconomic status, also driven by the influx of foreign immigrants 
(Rasam et al., 2019). In general, the prevalence of the disease can be due to the 
increasing number of HIV/AIDs patients, the emergence of multi-drug resistant TB, 
congregational transmission, and the high influx of foreign labors from high TB 
burden (Brennan, 1997).  
Besides, the problems of TB remained unsolved due to the existence of drug-
resistant TB (558 000 people) is resistant to the most effective first-line drug which 
is rifampicin (RR-TB). The multidrug-resistant TB (MDR-TB) patients have been 
developed due to the mycobacteria that show high-level resistance to both isoniazid 
and rifampicin, with or without resistance to other anti-TB drugs (Ormerod, 2005). 
Another issue is the prevalence of extensively drug-resistant TB (XDR-TB) 
identified as MDR-TB with additional resistance to any fluoroquinolone and at least 
one of three injectable drugs used for TB treatment: amikacin capreomycin, 
kanamycin (Parsons et al., 2011). It occurs due to the diagnosis that depends on 
confirming isolated organism’s drug susceptibility pattern, which is often either very 
limited or non-existent in many countries with high burden of disease and only 
possible in rich-resource settings. Drug-resistance should be strongly suspected in 
persons in TB treatment failure cases (Ormerod, 2005). 
Until now, an attenuated strain of Mycobacterium bovis termed Bacillus 
Calmette-Guerin (BCG) is the only vaccine present and available for prevention of 
TB (Tang et al., 2014) and the BCG immunization is considered effective in 
children, providing defense against severe and disseminated tuberculosis by 80% 
(Trunz et al., 2006) but has limited or largely ineffective on adult pulmonary TB 
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(Reyes et al., 2013b). About 45-85% of mortality in HIV infected patients related 
with the TB delay diagnosis and initiation of appropriate medication more than 3 
weeks after the symptom presentation (Devi et al., 2003). Therefore, an early 
diagnosis of TB or latent TB (LTBI) identification will help in the better 




Figure 2.1 The map of an estimated TB incidence rates in 2018 worldwide. Source: (World Health Organisation, 2019).
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2.1.1 An Aetiology of Tuberculosis  
The aetiology agent of TB in human is Mycobacterium tuberculosis (M.tb). 
The M.tb is a Gram-positive bacteria (Goulding et al., 2004) species in the family 
Mycobacteriaceae that was first discovered by a German physician, Robert Koch in 
1882 and a most well-known species, infecting the human population and also able 
to transmit the infection to animals that have contacted with the human. It is 
categorized as the group of Mycobacterium tuberculosis complex (MTBC) together 
with Mycobacterium canettii, Mycobacterium africanum, Mycobacterium microti, 
Mycobacterium bovis, Mycobacterium caprae and Mycobacterium pinnipedii that are 
genetically very similar (Forrellad et al., 2013b; Murray et al., 2015). The genome of 
M.tb comprises of 4,411,529 base pairs, consists of 4,000 genes, and has very high 
cytosine and guanine content that is expressed in the protein's biased amino acid 
content (Cole et al., 1998). The bacterium is around 0.5 µM in diameter, 1-4 µM in 
length and it is an aerobic intracellular pathogen (Welin, 2011). 
The characteristics features of the tubercle bacillus include slow growth, 
dormancy, complex cell envelope, intracellular pathogenesis and genetic 
homogeneity. It takes typically 24 hours of doubling time for M.tb generated in 
synthetic medium or infected animal (Ducati et al., 2006). The state of dormancy in 
which bacillus remains latent within infected tissue may indicate its vital metabolic 
activities shutdown and survives in its host for a long time by operating certain key 
activities which are essential for its survival (Jee et al., 2018). By deciphering M.tb 
whole genome sequence done before by Cole and his colleagues, the dormancy is 
believed to be entirely a physiological phenomenon (Cole et al., 1998) but, it is now 
thought to be a well programmed event and regulated by number of factors such as 
hypoxia, known to be one of the main strength behind this phenomenon while small 
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heat shock protein, 16 kDa is crucial for the maintenance of dormancy in M.tb (Jee et 
al., 2018) as discussed later in this chapter. However, as immunity becomes weaker 
due to immune suppression or ageing, the dormant bacteria reactivate and often 
cause disease outbreak many decades after the initial infection (Cole et al., 1998). 
The cell envelope of M.tb that have a G+C rich contents of 65.6% that 
contains an additional layer beyond the peptidoglycan that is exceptionally rich in 
unusual lipids, glycolipids and polysaccharide (Kolattukudy et al., 1997; Cole et al., 
1998). The arrangement structure of the lipids and glycolipids on the exterior 
mycobacterial cell envelope’s surface passively confers upon the bacilli properties 
such as impermeability to toxic macromolecules, a strong resistance to degradation 
by host enzymes, and inactivation of reactive oxygen and nitrogen derivatives (Korf 
et al., 2005). Several cell wall structures of M.tb have been identified as representing 
a pathogen-associated molecular patterns (PAMP), including the glycolipid 
lipoarabinomannan (LAM), soluble tuberculosis factor, and lipopeptides which are 
essential for pathogen survival (Korf et al., 2005). 
Besides, the macrophages are critical both allowing and in linking the host to 
innate and adaptive immunity. It facilitates the activation and recruitment of T cells 
to contain the mycobacteria within granulomas in the lung and even can replicate 
within the harsh environment of macrophages, sequestered in poorly acidified 
phagosomes that do not fuse with lysosomes. The M.tb also can evade macrophages 
bactericidal function by inhibiting interferon (IFN)-γ-mediated signalling and has 
been reported to interfere with multiple signalling pathways, antigen presentation and 
transcriptional responses within the macrophage, however the mycobacterial genes 
that involved are largely unknown (Rengarajan et al., 2005). 
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Once the bacterium is taken up in the form of infected droplets released from 
an infected individual's lungs, typically by coughing and sneezing, a M.tb is 
transmitted promptly. Figure 2.2 and Figure 2.3 show illustrated of the formation of 
the granuloma and infection process of M.tb. Upon inhalation, the resident alveolar 
macrophages and dendritic cell (DC) phagocytose the bacterium and generate signals 
for the induction of the cell-mediated immune response. However, the mycobacteria 
may persist and subvert the killing mechanism to allow replication as intracellular 
parasites. The initially infected cells release pro-inflammatory cytokines resulting in 
more DC, neutrophils and monocytes being recruited from the blood stream and the 
infected DC become triggered and migrate to the local lymph node, thereby 
activating specific T cells. The cytokines IL-12 and IL-18 from the infected cells 
induce Natural Killer (NK) cell activity, and NK cells in turn produce IFN-γ, which 
stimulates macrophages to produce Tumour Necrosis Factor alpha (TNF-α) and 
microbicidal substances (Keane et al., 1997; Korbel et al., 2008). 
The granuloma is formed through cytokine and chemokine signalling. In 
granuloma, macrophages are further differentiating into extracellular matrix protein 
and epithelioid cells or foamy outer cuff of fibroblasts. Thereby, the bacilli are to be 
contained for years even decades, persisting in a dormancy or slowly-replicating 
state until the granuloma fails due to immunosuppression and is unable to prevent the 
growth (Russell et al., 2009; Forrellad et al., 2013a). The mechanism that would 
reduce the ability for macrophages to function as protected sanctuaries for TB as it 
coincides with the reduction of bacterial growth in lung and the onset of adaptive 
immunity and may be significant benefit to the host. Conversely, killing of alveolar 
macrophages may benefit the mycobacteria by reducing phagocyte numbers and 
probably interfering with cell-mediated immunity induction. In active disease, the 
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granuloma centre become caseous, restraining necrotic macrophages in the lung that 
form advanced TB cavities. When the structure rupture, contagious bacilli spill into 
the airways, allowing new individuals to inhale (Keane et al., 1997; De Chastellier, 
2009).  
The pulmonary TB (lungs TB) is the primary site of infection, resulting in 
symptoms such as chronic bloody coughs, night sweats and weight loss which are the 
most severe clinical manifestation of M.tb infection. However, it also able to spread 
the infection to more distant sites in the body (extrapulmonary TB), such as 
peripheral lymph nodes, kidneys, brain and bones and this extrapulmonary TB can 
manifest itself as pericarditis, meningitis, or spinal TB (Donoghue, 2009). The 
development of new treatments, vaccines and diagnostic tools to help prevent or 
control this pandemic require a better understanding of the mechanisms involved in 





Figure 2.2 The diagram granuloma mechanism formation after the M.tb infection in a human. 
 
The resident alveolar macrophages (Mθ) phagocytose inhaled bacteria causing a pro-inflammatory response and recruitment of cells of innate and 
adaptive immune systems, and the formation of granuloma. The bacilli can contain within the structure until immune controls fails which lead to 





Figure 2.3 The summary of M.tb infection process from an early infection until development of active TB and LTBI. 
 
The life cycle of M.tb once inhaled by a human can last for 4-6 weeks while the stage of latent TB can stand for years even decades. The failure 




2.1.2 Diagnosis of Tuberculosis 
Inhalation of contaminated droplets from an infected person with TB can be 
either: 1) eradicated by immune system of the host; 2) contained as latent infection; 
3) progress towards the active disease. Less than 10% of infected individuals 
experience active TB throughout their lifetime (Gengenbacher and Kaufmann, 2012) 
and another approximately 90% individuals are effective in suppressing the infection 
and remain in latent state, identified as a state of persistent immune response to M.tb  
antigens stimulation without clinically manifested active TB evidence (Ilievska-
Poposka et al., 2018). An individual with LTBI has no symptoms of active TB and 
does not feel ill upon infected with the M.tb. Nevertheless, the risk of developing 
active TB in immuno-compromising situations such as patients with co-infection 
with human immunodeficiency virus (HIV)/acquired immunodeficiency syndrome 
(AIDS) or chronic inflammatory diseases or diabetes/obesity is increased (Barry et 
al., 2009). 
Several diagnostic assays and techniques were available for detection of the 
M.tb in LTBI or active TB stage. The techniques include chest x-rays, sputum smear 
microscopy, culture, rapid molecular tests, tuberculin skin test, IFN-γ release assays, 
phage amplification assays and others. The chest X-ray (CXR) is a rapid imaging 
technique that identifies abnormalities of lungs and is used to diagnose thoracic 
cavity conditions including the airways, lungs, ribs, heart and diaphragm., The CXR 
has been one of the primary tools for TB screening historically, which had high 
sensitivity mainly for pulmonary TB. However, CXR has low specificity, although 
some CXR abnormalities are rather specific to pulmonary TB (e.g. cavities), many 
CXR abnormalities that are consistent with pulmonary TB are also seen in several 
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other lung diseases (WHO, 2016). Therefore, another test is required to accompany 
to CXR diagnosis, as relying solely on CXR for TB diagnosis will lead to 
overdiagnosis and underdiagnosis (Koppaka and Bock, 2004). 
 
Sputum smear microscopy test is another technique that usually used for the 
M.tb identification. Despite it low cost technique, it has major drawback such as poor 
sensitivity which is estimated at 50% (Rotherham et al., 2012), time consuming, poor 
specificity and false-positive/negative results (He et al., 2016). This technique also is 
not applicable for HIV-coinfected patients and for children because of the decreased 
pulmonary bacillary loads in these patients. Additionally, in resource-poor countries, 
there are many smear microscopy laboratories but it is single room and understaffed 
with poorly maintained microscopes and some of these laboratories lack of clean 
water supplies and electricity (Parsons et al., 2011). 
Another available technique for diagnosis is by culturing the M.tb bacteria in 
the lab. The culture-based method is the most sensitive to detect M.tb. in infected 
patients however, it requires more developed laboratory resources and it can take up 
to 12 weeks to provide the results and high standard of technical competence 
personnel is needed (Rotherham et al., 2012; WHO, 2018). Even the most rapid 
culture technique such as radiometric liquid culture (BACTEC) been used, it still 
requires an average of 13 days to become positive and potential risk of cross 
contamination is high (Piersimoni et al., 2001).  
Rapid molecular tests have been introduced to overcome sputum microscopy 
and culture-based identification technique such as Loop-mediated Isothermal 
Amplification (LAMP), Xpert MTB/RIF, GenoType Line-Probe Assays (LPA), 
FluoroType MTB and others (Eddabra and Benhassou, 2018). Among all, Xpert® 
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MTB/RIF assay (Cepheid, USA) is the only rapid test currently approved by World 
Health Organisation (WHO) as the first-line diagnostic that can provide fast result 
within 2 hours and has much accuracy than sputum smear microscopy (WHO, 2018). 
However, it is costly especially to low and middle income countries that wish to 
implement this technology is the cost. This technology may incur US$9.98 per 
sample even after the announcement of a global price reduction for Xpert MTB/RIF 
cartridges (Schnippel et al., 2013; Van Rie et al., 2013) which not affordable by the 
poor countries. In addition, it has been estimated that the sensitivity of a single Xpert 
test is only 62-79% to detect M.tb in all negative smear microscopy result which is 
inadequate, although it is substantially better than sputum smear microscopy 
technique (Schnippel et al., 2013). 
However, all the rapid test is not for LTBI diagnosis and treatment 
indications are based on epidemiological, clinical, laboratory and patient acceptance 
criteria (Cohn et al., 2000). The identification of LTBI offers an opportunity for 
initial treatment and prevent latent infection reactivation which lead to active disease, 
particularly in those with compromised immune systems (Ilievska-Poposka et al., 
2018) and early treatment of LTBI reduces risk of progressing to future disease by 
75-90%, hence identifying individuals with LTBI has both individual benefits and 
substantial societal (WHO, 2008). The in vivo, century old tuberculin test (TST) and 
the ex vivo, interferon-γ release assays (IGRAs) are the two techniques that widely 
used to detect LTBI and previous TB infection (Zhou et al., 2017).  
 
The TST test or Mantoux test based on principles of deferred oversensitivity 
to recruit T cells memory to the site on an intradermal injection of purified protein 
derivative (PPD) of M.tb. The test is limited in use by its poor specificity due to 
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cross-reactivity with previous BCG vaccination and non-tuberculous mycobacteria 
(NTM), (Fu et al., 2009; Zhou et al., 2017). The other limitations of the TST include 
the necessary of inter-observer variability, scheduling a reading visit and the 
boosting phenomenon. In immuno-compromised patients, young people and the 
elderly, the false-negative results may be common (Cohn et al., 2000). 
The IGRAs are designed as an aid to TST for the LTBI diagnosis due to their 
logistical advantages and improved specificity over TST (Herrera et al., 2011). The 
IGRAs, specifically the QuantiFERON-TB Gold test (Cellestis) and T-SPOT. TB 
test (Oxford Immunotec) have been developed to detect and quantify the in vitro 
IFN-γ releases from T cells stimulated by TB-specific antigen in blood samples 
(Pollock et al., 2014). The Cellestis uses an enzyme-linked immunosorbent assay 
(ELISA) to measure the amount of IFN-γ produced, and the QFT-Gold in-tube 
(GIT), recent version of the QuantiFERON enables blood to be collected directly into 
pre-coated tubes to reduce sample processing and facilitate incubation. While T-
SPOT TB assay uses an enzyme-linked immunospot assay to measure the number of 
IFN-γ-producing cells on pre-coated plates.  
Both assays are available with a positive control (phytohaemagglutinin) and 
use highly specific antigens of  M.tb such as CFP-10 and ESAT-6 which are absence 
in any BCG strain or in most environmental mycobacteria, thus providing specificity 
over TST (Herrera et al., 2011). The IGRAs, despite its high specificity, it is 
expensive and required particular expertise, that presents a barrier in resource-limited 
settings (Pollock et al., 2014). 
Overall, both TST and IGRAs are valuable screening tool for LTBI detection 
however, it should be noted that neither of these immune-based tests performs with 
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optimum sensitivity in individual who are immuno-compromised or able 
discriminating between active and past disease from latent infection, which is a 
major issue in TB endemic areas (Goletti et al., 2016; Zhou et al., 2017) 
Therefore, TB control strategy recommended by WHO is Directly Observed 
Treatment and Short-course drug therapy (DOTS) programs which is the most 
successful treatment strategy available for TB control and one of the most rapidly 
expanding and effective intervention since of the 1990s (Aziah, 2004). To ensure 
compliance, the patients are observed when they take their medication since non-
compliance is a major contributor to the antibiotic resistance development (Dye and 
Williams, 2010). The TB delayed diagnosis may enhance the infection transmission, 
increase the risk of death, and maybe the reason why TB incidence has not decreased 
significantly, hence there is a crucial need for new, simple, sensitive and rapid point-
of-care diagnosis as well as quality assurance programs, investments in laboratory 
infrastructure and well-trained personnel. 
2.1.3 Biomarkers for TB Diagnosis 
Specific biomarkers are important prerequisite for the development of 
diagnostic reagents or improved available vaccines for TB disease. The 
mycobacterial antigens such as MPT64, Mtb81, 38 kDa, MPT48, ESAT-6, CFP-10, 
16 kDa and others have been evaluated for their serodiagnosis potential for both 
latent TB and active TB (Wu et al., 2011). 
One of the major M.tb antigens is a 24 kDa secretory protein, also known as 
MPT64. The SD MPT64TB Ag Kit, a new rapid immunochromatographic test kit 
was evaluated for rapid identification of M.tb. for detection of the antigen isolated 
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using mouse monoclonal MPT64 antibody (Kumar et al., 2011). The previous report 
also reconfirm that the test is a simple and cost-effective method for differentiating 
mycobacterial cultures as Mycobacterium tuberculosis complex (MTBC) from non-
tuberculous mycobacteria (NTM). However, if the test results are negative, 
alternative specific identification tests need to be carried out to confirm the MTBC 
and NTM isolates (Shenoy and Mukhopadhyay, 2014; Sharma et al., 2015). 
Besides, Mtb81 protein, identified by serological proteome analysis has 
appears to be a potential antigen for the serodiagnosis of TB, especially for patients 
co-infected with HIV (Hendrickson et al., 2000). Nevertheless, the use of single 
antigen alone for TB diagnosis has not been able to achieve sufficiently high 
sensitivity and specificity at the same time. Therefore, it is worth pursuing to 
evaluate the response of antibodies to multiple M.tb antigens to recognize superior 
antigens and their possible combinations for serological diagnosis of TB (Yan et al., 
2018) which is certainly time-consuming and less productive. 
Since many studies suggest that the response of the antibody to M.tb antigens 
is diverse among individuals, thus the antibodies detection against a single antigen 
normally has a low sensitivity for TB diagnosis, particularly in bacterium negative 
cases. Therefore, another approach for evaluating antibodies against 38 kDa antigen 
protein and other major antigens was introduced. The data suggest that 
characterization of antibodies against 38-kDa, MTB48, and CFP-10/ESAT-6 fusion 
antigens can increase the specificity and sensitivity for active TB diagnosis. 
Moreover, compared to single antigen, the positive antibody responses rates to two 
or more antigens were significantly higher (Wu et al., 2011). Nonetheless, additional 
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efforts should be made for serological detection of smear- or culture-negative 
infections (Lodes et al., 2001). 
Besides, a report have been shown that a Camel/Llama Heavy Chain 
monoclonal antibody (VHH) is demonstrated specific and exclusively recognized the 
16 kDa heat shock protein. The 16 kDa protein had been shown to bind in 
immobilized lysate in direct ELISA tests and soluble antigen by surface plasmon 
resonance (SPR) analysis (Trilling et al., 2011). However, the isolation of the 
antibody may require the use of larger animals that need to be regularly immunize 
with 2-3 immunogens at the same time and re-use the animal is after waiting at least 
6 months in case of failure of antibody isolation. It also required the selection of the 
bio-hazardous bacteriophage which is greatly outweighed by the ability to screen 
generate and control the resulting VHHs rapidly and reliably (Bever et al., 2016) 
which is inconvenient process and time-consuming. 
2.1.3 (a) Aptamers for TB Diagnosis 
  Due to some limitations encountered by antibodies for TB detection using 
several significant biomarkers, aptamers have been generated to substitute the use of 
antibody against M.tb. antigens. For example, a functional ssDNA aptamers (CE24 
and E15) that specific bound to ESAT6-CFP10 (CE) protein had been developed that 
showed the highest specificity and binding affinity and further detected using 
ELONA for both proteins in serum samples from active pulmonary TB patients, 
extrapulmonary TB patients and healthy donors. The report was convinced with a 
good correlation was observed between aptamer-based ELONA and T-SPOT TB 
assay. However, some optimisations were required and large sample tests to further 
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validate their aptamer-based method of detecting antigens in human samples (Tang et 
al., 2014). 
Another ssDNA aptamers were selected for detection of M.tb secreted protein 
MPT64 that showed a good specificity and sensitivity values (90% and 91.3% 
respectively), and be less likely to give false positive results. The recent study did not 
compare the binding mechanism of aptamer-MPT64 with antibody-MPT64 because 
of size differences and steric hindrance (Sypabekova et al., 2017). However, this 
study is need to be improved in case of low signal occurs by labelling with 
nanoparticles or fluorescent reporting molecules for effective detection of TB and do 
another validation for specificity and sensitivity test from non-tuberculous 
mycobacteria and bacillus Calmette-Guérin strains culture samples. 
Recently, a DNA aptamer against HspX have been isolated as an alternative 
diagnostic reagent for accurate tuberculous meningitis (TBM) diagnosis. Aptamer 
H63 SL-2 M6 showed interaction against HspX with high specificity and affinity 
(Kd ∼9.0×10−8 M). By using Aptamer Linked Immobilized Sorbent Assay 
(ALISA), H63 SL-2 M6 significantly distinguished between cerebrospinal fluid 
specimens (CSF) from TBM and non-TBM subjects. Nevertheless, a larger study 
involving a multiple  age group and ethnicity is needed to validate these findings and 
determine the diagnostic efficacy of aptamer-based rapid test in the clinical setting 
(Dhiman et al., 2018). In addition, the used of DNA aptamers have several 
disadvantages as discussed in the section 2.2.1 (a). 
In latent infection, low numbers of bacteria are presence usually and the 
physical microenvironment in which bacteria survive is thought to involve restricted 
access to nutrients, oxygen, and low pH will induces a massive up-regulation of the 
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production of this protein to adapt to low-oxygen or nutrient deficit dormancy, which 
is associated with a thickened cell envelope, providing evidence that 16 kDa as 
potential targets of biomarkers of  LTBI (Wilkinson et al., 1998; Demissie et al., 
2006; Zhang et al., 2015).  
The 16 kda heat shock protein (HSP) is encodes by Rv2031c/hspX/acr (Yuan 
et al., 1998; Jee et al., 2018) and it is belongs to the α-crystallin super-family of heat 
shock proteins (HSPs) and has been variably referred to as sHsp 16, Hsp.16.3, Acr 
and MPT63 (Devi et al., 2002). Though it has been classified as HSP family, it is not 
a heat induced protein as name implies but it is hypoxia induced oxygen (Yuan et al., 
1996). The important of 16 kDa protein is represented by the fact that deficiency of 
this protein deteriorates the M.tb tolerance to anaerobiosis. Thus, it is invoked as a 
potential candidate facilitating the pathogen's survival during hypoxia, a situation 
close to latency (Mushtaq et al., 2015) that becomes a key aspect of the active 
participation of the bacterium and the pathogen's lifestyle in the formation of 
granulomas (Hu et al., 2006). 
The identification of 16 kDa antigen protein as the major membrane protein 
proposes that the protein does not function purely cytoplasmically (Lee et al., 1992). 
The exact cellular location is unknown till date, although peripherally associated 
with inner membrane and occurred outside of the cell wall (Jee et al., 2018). It was 
also not found in culture supernatant (Verbon et al., 1990) as concordance with the 
study by Trilling et al on Camel/Llama Heavy Chain monoclonal antibody (VHHs) 
against 16 kDa protein. The ELISA signal of the VHHs to culture medium or whole 
cells of the M.tb could be hardly observe, while strong signal occurred in cell lysate 
that proved 16 kDa protein is not released into culture supernatant. Thus, lysis of 
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bacteria will be require before detection in sputum due to this subcellular localization 
(Trilling et al., 2011). 
The 16 kDa protein exhibited its chaperonin property by preventing the 
thermal denaturation of alcohol dehydrogenase in vitro (Yuan et al., 1996).  The 
modulation of its chaperone activity by exposing its hydrophobic surface for 
interaction with denaturing protein and the protein structure will highly stable and 
flexible, thus highly adapted for its function (Yang et al., 1999). In addition, its 
chaperone activity is exclusively temperature dependant (Fu and Chang, 2004) and 
even pre-incubation at 1000°C resulted in enhanced chaperone like activity without 
altering the surface hydrophobicity (Jee et al., 2018). 
The 16 kDa is indispensable for growth of the bacillus as a study on gene 
knockout suggested that it is an inevitable requirement for M.tb normal growth 
during infection (Yuan et al., 1998). The deletion of hspX gene resulted in bacterial 
growth enhancement while its overexpression delayed the growth of bacilli during 
early phase of mice infection which associated to latency phase (Hu et al., 2006). 
Moreover, it is the most prominent protein in the extract of M.tb during latency 
(Yuan et al., 1998). It was found to be involved in the thickening of cell walls, 
therefore indirectly facilitating dormancy since the thickened cell wall helps the 
bacilli to withstand the hostile environment during infection (Cunningham and 
Spreadbury, 1998). 
In addition, the 16 kDa protein could be used as a marker for LTBI, even in a 
BCG vaccinated population (Siddiqui et al., 2011) as it has been found that T-cells 
can respond to this antigen in order to distinguish between latently infected and BCG 
vaccinated individuals (Geluk et al., 2007). A study has also been reported on 
